Suppliers and packagers for generic pharmaceutical drug: CHLORHEXIDINE GLUCONATE

CHLORHEXIDINE GLUCONATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Xttrium	EXIDINE	chlorhexidine gluconate	AEROSOL, METERED;TOPICAL	019127	NDA	Xttrium Laboratories, Inc.	0116-0505-01	946 mL in 1 BOTTLE (0116-0505-01)	2006-01-01
Xttrium	EXIDINE	chlorhexidine gluconate	AEROSOL, METERED;TOPICAL	019127	NDA	Xttrium Laboratories, Inc.	0116-0505-02	946 mL in 1 BOTTLE (0116-0505-02)	2006-01-01
Xttrium	EXIDINE	chlorhexidine gluconate	AEROSOL, METERED;TOPICAL	019127	NDA	Xttrium Laboratories, Inc.	0116-1060-18	535 mL in 1 BOTTLE, PLASTIC (0116-1060-18)	2023-11-15
Xttrium	EXIDINE	chlorhexidine gluconate	AEROSOL, METERED;TOPICAL	019127	NDA	Xttrium Laboratories, Inc.	0116-1060-32	946 mL in 1 BOTTLE, PLASTIC (0116-1060-32)	2023-11-15
Xttrium	EXIDINE	chlorhexidine gluconate	AEROSOL, METERED;TOPICAL	019127	NDA	Xttrium Laboratories, Inc.	0116-1060-33	946 mL in 1 BOTTLE, PLASTIC (0116-1060-33)	2023-11-15
Sage Prods	CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate	CLOTH;TOPICAL	021669	NDA	Sage Products LLC	53462-705-20	2 CLOTH in 1 PACKAGE (53462-705-20)	2006-02-01

Chlorhexidine Gluconate Suppliers: Market Landscape and Key Players

Last updated: February 19, 2026

Chlorhexidine gluconate (CHG) is a broad-spectrum antiseptic and disinfectant used in a variety of healthcare and consumer products. The market for CHG is characterized by a limited number of primary manufacturers and a complex supply chain involving intermediaries and formulators. Key supply chain considerations include raw material sourcing, manufacturing capacity, regulatory compliance, and quality control.

What is the Global Demand for Chlorhexidine Gluconate?

Global demand for CHG is driven by its widespread application in healthcare settings for surgical scrubs, skin antisepsis, and oral hygiene products. The increasing prevalence of healthcare-associated infections (HAIs) and the growing emphasis on infection control protocols are significant demand drivers. Furthermore, the expanding use of CHG in over-the-counter (OTC) oral care products, such as mouthwashes and dental rinses, contributes to sustained demand.

The global antiseptics and disinfectants market, of which CHG is a component, was valued at approximately USD 58.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030 (1). This growth is supported by factors such as increased healthcare expenditure, rising awareness of hygiene, and the development of new antimicrobial formulations.

Specific to CHG, market research indicates a steady demand due to its efficacy and established safety profile. For instance, the oral care segment, a major consumer of CHG, is a significant contributor to this demand. The global mouthwash market, in particular, was valued at USD 6.08 billion in 2022 and is expected to expand at a CAGR of 5.5% from 2023 to 2030 (2).

Who are the Primary Manufacturers of Chlorhexidine Gluconate?

The production of active pharmaceutical ingredients (APIs) like CHG is concentrated among a select group of global manufacturers. These companies operate specialized facilities compliant with stringent Good Manufacturing Practices (GMP).

Primary manufacturers include:

• Agrocon S.A. Located in Argentina, Agrocon is a significant producer of CHG, serving both domestic and international markets. Their production is a key factor in global supply availability.
• Guanajuato Industrial S.A. de C.V. (GISSA) based in Mexico, GISSA is another prominent producer of CHG. Their manufacturing operations are crucial for meeting the demand from North and South American markets.
• Kemira Oyj This Finnish chemical company has a presence in CHG manufacturing, contributing to the European supply chain and global markets.
• Anupam Rasayan India Limited While primarily focused on custom synthesis, Anupam Rasayan has the capability and has been involved in the production of CHG, adding to the global manufacturing footprint, particularly from the Indian subcontinent.

These primary manufacturers are responsible for synthesizing the CHG molecule from precursor chemicals. Their output is typically sold in bulk as an API to formulators, distributors, or other chemical companies who then incorporate it into finished products.

What are the Key Supply Chain Dynamics for Chlorhexidine Gluconate?

The CHG supply chain involves several critical stages, from raw material procurement to finished product distribution. Disruptions at any stage can impact availability and pricing.

Raw Material Sourcing: The synthesis of CHG requires specific precursor chemicals. The availability and cost of these raw materials, often derived from petrochemical feedstocks, can fluctuate based on global chemical market dynamics and geopolitical factors. Supply chain resilience relies on diversified sourcing for these key inputs.

Manufacturing and Production Capacity: Production of CHG API requires specialized chemical synthesis processes and significant capital investment in manufacturing facilities. Capacity expansions are strategic decisions for manufacturers, influenced by anticipated market demand and regulatory hurdles. The number of primary manufacturers means that capacity constraints at any single facility can have a noticeable impact on the global supply.

Quality Control and Regulatory Compliance: CHG is an API used in pharmaceutical and healthcare products. Therefore, all manufacturing processes must adhere to strict quality control standards and regulatory requirements, such as GMP, set by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must maintain certifications and undergo regular inspections, which adds to the cost and complexity of production.

Distribution and Logistics: Once manufactured, CHG API is transported to formulators globally. This involves specialized handling and storage to maintain product integrity. Logistics networks are critical for timely delivery and can be affected by transportation costs, customs regulations, and international trade policies.

Intermediaries and Formulators: A significant portion of the CHG supply chain involves intermediaries and formulators. These entities purchase bulk CHG API and then develop and manufacture finished products. This includes pharmaceutical companies producing prescription mouthwashes and wound care solutions, as well as consumer goods companies manufacturing OTC dental products and personal care items.

Geographic Concentration: The primary manufacturing of CHG API is geographically concentrated in a few regions, notably North America (Mexico), South America (Argentina), Europe (Finland), and increasingly, Asia (India). This concentration presents both opportunities for specialized expertise and potential risks related to regional supply chain disruptions.

What are the Regulatory Considerations for Chlorhexidine Gluconate Products?

Regulatory oversight for CHG is critical due to its use in human health applications. Different product categories and jurisdictions impose specific requirements.

API Manufacturing: Manufacturers of CHG API must comply with GMP guidelines. In the United States, this typically involves facility registration with the FDA and adherence to the U.S. Pharmacopeia (USP) monograph for chlorhexidine gluconate. Similar pharmacopeial standards exist in Europe (European Pharmacopoeia, EP). Compliance documentation, such as Drug Master Files (DMFs), is often required by regulatory bodies.

Finished Product Approval: Products containing CHG require separate regulatory approvals.

• Pharmaceutical Products: Prescription medications containing CHG, such as certain wound care solutions or dental rinses, are regulated as drugs. This requires rigorous clinical trials to demonstrate safety and efficacy, followed by New Drug Application (NDA) or Marketing Authorisation Application (MAA) submissions to agencies like the FDA or EMA.
• Over-the-Counter (OTC) Products: OTC products like antiseptic mouthwashes are often regulated as either drugs or under specific OTC monographs, depending on the jurisdiction and intended use. For example, in the U.S., CHG mouthwashes are often regulated under the FDA's OTC drug regulations.
• Cosmetic Products: While CHG's primary use is antiseptic, some formulations might fall under cosmetic regulations if their claims are limited to cleansing or freshening without therapeutic claims. However, given CHG's potent antimicrobial properties, such classifications are rare and tightly scrutinized.

Labeling and Claims: Regulatory bodies dictate the claims that can be made for CHG products. For pharmaceutical products, claims must be supported by robust scientific evidence. For OTC products, claims must align with approved monographs or specific marketing authorizations. Misleading claims or unproven therapeutic benefits can lead to regulatory action.

Import/Export Regulations: International trade of CHG API and finished products is subject to import and export regulations in each country. This includes adherence to customs procedures, potential tariffs, and specific import/export licensing requirements.

Who are the Key Formulators and Distributors of Chlorhexidine Gluconate Products?

Beyond the primary API manufacturers, a diverse range of companies formulates and distributes CHG into finished products for end-users. These entities represent the commercial interface with consumers and healthcare providers.

Pharmaceutical Companies:

• Dentaid S.L.: A Spanish pharmaceutical company known for its oral care products, including mouthwashes containing CHG.
• Colgate-Palmolive Company: A global consumer goods giant that offers a range of oral hygiene products, some of which utilize CHG for its antiseptic properties.
• Procter & Gamble (P&G): Another major consumer goods corporation with a portfolio that may include oral care products featuring CHG.
• 3M Company: Known for its healthcare products, 3M supplies CHG-containing solutions for wound care and surgical prep.

Specialty Chemical and Ingredient Suppliers:

• BASF SE: While not a primary API manufacturer of CHG itself, large chemical companies like BASF are often involved in the broader chemical supply chain and may offer intermediates or related chemical services.
• Univar Solutions: A global distributor of chemicals and ingredients that supplies CHG and other raw materials to formulators across various industries, including pharmaceuticals and personal care.

Contract Manufacturers (CMOs): Many companies rely on CMOs to formulate and package their CHG-based products. These CMOs have the expertise and infrastructure to produce finished goods according to specific client requirements and regulatory standards.

Distributors: A network of national and international distributors plays a crucial role in getting CHG-containing products from manufacturers and formulators to retail shelves and healthcare institutions. These can include broad-line pharmaceutical distributors, specialized medical supply companies, and wholesalers.

What are the Market Trends and Future Outlook for Chlorhexidine Gluconate?

The market for CHG is expected to see continued growth, driven by established applications and emerging opportunities.

Increasing Focus on Infection Control: The persistent threat of HAIs and the ongoing global focus on hygiene and infection prevention in healthcare settings will continue to be a primary demand driver for CHG-based disinfectants and antiseptics. Public health initiatives and hospital protocols emphasizing rigorous infection control measures support this trend.

Growth in Oral Care Segment: The expanding market for oral hygiene products, particularly in emerging economies, will fuel demand for CHG in mouthwashes and dental rinses. Consumer awareness of the link between oral health and overall well-being, coupled with increased disposable income, contributes to this growth.

Advancements in Formulation and Delivery: Research and development efforts may focus on enhancing CHG's efficacy, reducing potential side effects, and improving its delivery mechanisms. This could include the development of new formulations for targeted applications, such as sustained-release dental rinses or enhanced wound healing products.

Geographic Market Expansion: Demand for CHG is projected to grow in developing regions where healthcare infrastructure is expanding and awareness of hygiene practices is increasing. This presents opportunities for market penetration by API manufacturers and formulators.

Regulatory Scrutiny and Antimicrobial Resistance: While CHG is highly effective, ongoing monitoring of potential antimicrobial resistance associated with its widespread use is crucial. Regulatory bodies may adjust guidelines based on emerging scientific data. However, CHG is not typically associated with significant resistance issues akin to antibiotics.

Supply Chain Resilience: Recent global events have highlighted the importance of robust and resilient supply chains. Companies will likely prioritize diversifying their sourcing of raw materials and API to mitigate risks associated with single-source dependency or geopolitical instability.

Sustainability Initiatives: As with many chemical manufacturing processes, there is an increasing focus on sustainable production methods. Manufacturers may invest in greener synthesis routes or waste reduction technologies, which could influence production costs and market perception.

Key Takeaways

The chlorhexidine gluconate market is characterized by a concentrated API manufacturing base, primarily located in Argentina, Mexico, Finland, and India. Demand is robust, driven by critical applications in healthcare for infection control and in the consumer market for oral hygiene products. The supply chain is complex, involving raw material sourcing, specialized manufacturing, stringent regulatory compliance (GMP, pharmacopeial standards), and extensive distribution networks. Formulators, including pharmaceutical and consumer goods companies, leverage bulk CHG API to produce a wide array of finished products. Future growth is anticipated due to ongoing infection control initiatives, the expanding oral care market, and potential for new product formulations, with an increasing emphasis on supply chain resilience and sustainable manufacturing practices.

Frequently Asked Questions

1. Are there any emerging alternative antiseptics that could displace chlorhexidine gluconate in its primary applications? While research into novel antimicrobial agents is ongoing, chlorhexidine gluconate's established efficacy, broad spectrum of activity, and favorable safety profile (when used as directed) make it a difficult agent to displace in its core healthcare and oral care applications. Alternatives like povidone-iodine and quaternary ammonium compounds are used in specific contexts, but CHG remains a preferred choice for many applications due to its particular characteristics.

2. What are the primary risks associated with the chlorhexidine gluconate supply chain? Key risks include reliance on a limited number of primary API manufacturers, potential fluctuations in raw material costs and availability, disruptions to global logistics and transportation, and the stringent and evolving regulatory landscape that requires continuous compliance. Geopolitical instability in manufacturing regions can also pose a risk.

3. How do regulatory approvals for CHG-based pharmaceutical products differ from those for OTC oral care products? Pharmaceutical products, particularly prescription items, require extensive clinical trials to demonstrate safety and efficacy, leading to New Drug Applications (NDAs) or Marketing Authorisation Applications (MAAs). OTC oral care products, while still regulated by agencies like the FDA, often fall under specific over-the-counter monographs or streamlined approval processes, focusing on established safety and efficacy for their intended uses, with claims generally limited to those permitted for OTC drugs.

4. What impact does the concentration of API manufacturing have on pricing and availability of chlorhexidine gluconate? The concentration of API manufacturing among a few key players can lead to price sensitivity and potential supply chain vulnerabilities. If a major manufacturing facility experiences an operational issue or if demand surges unexpectedly, it can lead to shortages and price increases. Conversely, increased competition or capacity expansions by existing players can exert downward pressure on prices.

5. Can chlorhexidine gluconate be used in veterinary medicine, and if so, what are the supply chain implications? Yes, chlorhexidine gluconate is also used in veterinary medicine as an antiseptic and disinfectant for animals. The supply chain for veterinary-grade CHG often parallels that for human applications, though regulatory standards and specific product formulations may differ. Demand from the veterinary sector adds another layer to the overall global consumption of CHG, influencing production volumes and distribution channels.

Citations

1. Grand View Research. (2023). Antiseptics and Disinfectants Market Size, Share & Trends Analysis Report. https://www.grandviewresearch.com/industry-analysis/antiseptics-disinfectants-market
2. Grand View Research. (2023). Mouthwash Market Size, Share & Trends Analysis Report. https://www.grandviewresearch.com/industry-analysis/mouthwash-market